JP Morgan analyst Samik Chatterjee maintains NetApp (NASDAQ:NTAP) with a Overweight and raises the price target from $85 to $90.
FDA Approves Arcutis’ ZORYVE Topical Foam, 0.3% For The Treatment Of Seborrheic Dermatitis In Individuals Aged 9 Years And Older
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use
ZORYVE foam
